Alcon AG | ALC - Beneficio Bruto En Ventas





Beneficio Bruto En Ventas Cambio Fecha
AstraZeneca USD 12.61B 225M 2026-03
Bayer EUR 5.35B 1.02B 2025-09
Essilor EUR 8.3B 547M 2025-12
Fresenius EUR 1.51B 214M 2025-12
Fresenius Medical Care EUR 1.39B 147M 2025-12
GlaxoSmithKline GBP 5.75B 429M 2026-03
GRIFOLS EUR 686.84M 56.95M 2025-12
Lonza CHF 1.29B 248M 2025-06
Merck EUR 2.96B 252M 2025-12
Novartis USD 10.25B 570M 2025-12
Philips EUR 2.29B 377M 2025-12
Roche Holding CHF 22.09B 10.04B 2025-12
Sanofi EUR 8.45B 1.31B 2025-12
Smith & Nephew USD 2.09B 117M 2025-12
Sonova Holding CHF 1.28B 205.2M 2025-12
UCB EUR 3.19B 621M 2025-12